Effects of 12 months of treatment with disease-modifying anti-rheumatic drugs on low and high density lipoprotein subclass distribution in patients with early rheumatoid arthritis: a pilot study
- PMID: 23311768
- DOI: 10.3109/03009742.2012.745013
Effects of 12 months of treatment with disease-modifying anti-rheumatic drugs on low and high density lipoprotein subclass distribution in patients with early rheumatoid arthritis: a pilot study
Abstract
Objectives: Patients with rheumatoid arthritis (RA) have increased cardiovascular risk. The aim of the present study was the assessment of low density lipoprotein (LDL) and high density lipoprotein (HDL) subclass distribution in patients with early RA (ERA, n = 30) compared with age- and sex-matched healthy subjects (n = 30), as well the effect of treatment for 12 months with the disease-modifying anti-rheumatic drugs (DMARDs) methotrexate and prednisone in this distribution.
Method: LDL and HDL subclass distribution was determined using a polyacrylamide gel-tube electrophoresis method.
Results: ERA patients exhibited increased levels of inflammatory markers and high disease activity score. ERA patients had higher serum levels of total cholesterol (TC), LDL cholesterol (LDL-C), and triglycerides (TG) whereas their serum HDL cholesterol (HDL-C) levels were significantly lower compared with controls. ERA patients exhibited significantly higher plasma levels of small dense LDL-C (sdLDL-C), leading to a significantly decreased mean LDL diameter. ERA patients had significantly decreased small HDL particles (HDL-3) concentration whereas serum levels of large HDL particles (HDL-2) did not differ compared with controls. Treatment with DMARDs resulted in a significant decrease in inflammatory markers and disease activity, along with a significant increase in HDL-C serum levels. The concentration of sdLDL-C did not change significantly during treatment. We observed a significant increase in the levels of large HDL-2 whereas the concentration of small HDL-3 did not significantly change.
Conclusions: Patients with ERA have increased sdLDL-C levels and decreased HDL-C levels because of decreased concentration of the small HDL-3 subclass. The administration of DMARDs induced a significant increase in HDL-C levels, which was attributed to the increase in large HDL-2 serum concentration.
Similar articles
-
Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy.Scand J Rheumatol. 2006 Mar-Apr;35(2):107-11. doi: 10.1080/03009740500474578. Scand J Rheumatol. 2006. PMID: 16641043
-
High HDL-cholesterol in women with rheumatoid arthritis on low-dose glucocorticoid therapy.Eur J Clin Invest. 2008 Sep;38(9):686-92. doi: 10.1111/j.1365-2362.2008.01994.x. Eur J Clin Invest. 2008. PMID: 18837746
-
Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab.J Rheumatol. 2006 Dec;33(12):2440-6. Epub 2006 Oct 1. J Rheumatol. 2006. PMID: 17014005 Clinical Trial.
-
Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies.Ann Rheum Dis. 2018 Jul;77(7):988-995. doi: 10.1136/annrheumdis-2017-212461. Epub 2018 Feb 20. Ann Rheum Dis. 2018. PMID: 29463520 Free PMC article. Review.
-
Increased lipid levels but unchanged atherogenic index in rheumatoid arthritis patients treated with biologic disease modifying antirheumatic drugs: published experience.Clin Exp Rheumatol. 2009 May-Jun;27(3):446-51. Clin Exp Rheumatol. 2009. PMID: 19604437 Review.
Cited by
-
N-Acetylcysteine overcomes epalrestat-mediated increase of toxic 4-hydroxy-2-nonenal and potentiates the anti-arthritic effect of epalrestat in AIA model.Int J Biol Sci. 2023 Aug 6;19(13):4082-4102. doi: 10.7150/ijbs.85028. eCollection 2023. Int J Biol Sci. 2023. PMID: 37705749 Free PMC article.
-
Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?Rev Diabet Stud. 2013 Summer-Fall;10(2-3):171-90. doi: 10.1900/RDS.2013.10.171. Epub 2013 Aug 10. Rev Diabet Stud. 2013. PMID: 24380091 Free PMC article. Review.
-
The effects of biologic agents on cardiovascular risk factors and atherosclerosis in rheumatoid arthritis patients: a prospective observational study.Heart Vessels. 2022 Dec;37(12):2128-2136. doi: 10.1007/s00380-022-02114-y. Epub 2022 Jun 24. Heart Vessels. 2022. PMID: 35739432
-
[Serum lipid profile in children with different subtypes of juvenile idiopathic arthritis].Zhongguo Dang Dai Er Ke Za Zhi. 2019 Jun;21(6):547-551. doi: 10.7499/j.issn.1008-8830.2019.06.009. Zhongguo Dang Dai Er Ke Za Zhi. 2019. PMID: 31208507 Free PMC article. Chinese.
-
Repurposing existing drugs for cardiovascular risk management: a focus on methotrexate.Drugs Context. 2018 Nov 14;7:212557. doi: 10.7573/dic.212557. eCollection 2018. Drugs Context. 2018. PMID: 30459819 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous